The lengthy timelines of drug development create a significant perception lag for AI's impact. Molly Gibson clarifies that molecules currently in clinical trials were designed years ago using nascent AI models. The true capabilities of today's more advanced AI platforms won't be evident in approved drugs for several more years.

While AI excels at screening vast compound libraries for potential drug candidates, it cannot overcome the ultimate bottleneck: the messy, complex, and poorly documented reality of human biology. The need for physical clinical trials remains the fundamental constraint on medical progress.

AI cannot yet revolutionize drug discovery because its strength is synthesizing existing knowledge. The problem is that humans only understand about 20% of the human body's biology, meaning the foundational dataset is too incomplete for AI to reliably predict outcomes for the unknown 80%.

While AI can accelerate the ideation phase of drug discovery, the primary bottleneck remains the slow, expensive, and human-dependent clinical trial process. We are already "drowning in good ideas," so generating more with AI doesn't solve the fundamental constraint of testing them.

Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.

Unlike coding, where AI models get immediate feedback on whether code runs, drug development faces immense delays. A biological hypothesis can take a decade and hundreds of millions of dollars to test in the clinic. This lack of rapid validation checkpoints is a core obstacle for AI's ability to learn and reliably improve drug target selection.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.

Contrary to popular belief, AI's role in drug discovery is marginal. Martin Shkreli argues the main hurdle is the billion-dollar, multi-year process of human clinical trials, an area where AI has little impact. The chemistry itself is a relatively solvable problem for experts.

Despite AI's power to predict drug candidates, the transition from digital discovery to real-world treatment is a major hurdle. The complex, slow, and expensive processes of manufacturing, clinical trials, and treating actual patients—the "analog world"—will temper AI's revolutionary impact on medicine.